Comparative Pharmacology
Head-to-head clinical analysis: JASCAYD versus NINTEDANIB ESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JASCAYD versus NINTEDANIB ESYLATE.
JASCAYD vs NINTEDANIB ESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JASCAYD (tasquinimod) is a selective allosteric inhibitor of S100A9, which binds to toll-like receptor 4 (TLR4) and receptor for advanced glycation end-products (RAGE). It modulates the tumor microenvironment by inhibiting myeloid-derived suppressor cell (MDSC) recruitment and function, reducing angiogenesis, and enhancing anti-tumor immune responses.
Nintedanib esylate is a tyrosine kinase inhibitor that binds competitively to the ATP-binding pocket of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). This inhibition blocks downstream signaling pathways involved in angiogenesis and fibrosis.
Adults: 300 mg orally twice daily with food.
150 mg orally twice daily, 12 hours apart, taken with food.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically relevant for once-daily dosing.
Terminal elimination half-life is approximately 10 hours in patients with IPF; steady state reached within 7 days.
Primarily renal excretion (80%) as unchanged drug; 20% fecal via biliary elimination.
Biliary/fecal: >90% (unchanged and metabolites); Renal: <1%
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor